The report by Chen sheds new light on resistance to abiraterone and is spurred in part by two observations. First, CYP17A1 inhibition with abiraterone deflects steroid synthesis away from pathways resulting in 19-carbon steroids (i.e., androgens) and toward those that produce 21-carbon steroids 8 , including a 4-or 5-fold increase in tissue progesterone concentrations 9 .
Second, the AR T878A mutation present in the LNCaP human cell line model of prostate cancer has broadened specificity such that progesterone functions as an AR agonist, and may drive tumor progression by way of this mechanism 10 . The investigators therefore hypothesized that androgen depletion along with rising progesterone due to abiraterone therapy would select for tumors that harbor this specific AR mutation ( Figure) .
RNA from a total of 18 tumors progressing on pharmacologic CYP17A1 inhibitors (17 patients receiving abiraterone and 1 ketoconazole) was interrogated from patients with CRPC.
Three of the patients treated with abiraterone were given single agent therapy and 14 were treated in combination with daily dutasteride (3.5 mg) and prednisone (5 mg). Of 18 patients, 3
had the AR T878A mutation detectable in progressing tumors. These 3 patients included the patient treated with ketoconazole (67.7% of AR mRNA reads), 1 patient treated with abiraterone alone (60.3% of AR mRNA reads), and 1 patient treated with abiraterone, dutasteride and prednisone (6.0% and 18.4% of AR mRNA reads from 2 liver biopsies). In tissue obtained prior to therapy from a liver lesion in the patient treated with abiraterone, dutasteride and prednisone, 0.09% of AR mRNA reads showed the T878A mutation, suggesting that this mutation preexisted at a low frequency and represented a cell population that was enriched with this combination of drugs. Analysis of genomic DNA obtained from these tumors confirmed these findings. None
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of the patients found to have this mutation had been previously treated with flutamide or nilutamide -agents that are known to function as agonists in the presence of the mutation. In addition to the analyses done in tumors from patients with metastatic CRPC, the AR T878A mutation was also found in a focus of localized prostate cancer that persisted after treatment in a neoadjuvant study of castration plus abiraterone for 24 weeks, prior to radical prostatectomy 9 ,
suggesting that earlier emergence of this mutation may occur when abiraterone is combined with upfront castration.
The lower frequency of the AR T878A mutation in patients treated with the combination of abiraterone, dutasteride and prednisone (1/14) as compared to abiraterone alone might indicate that dutasteride and/or prednisone inhibits enrichment of mutation-bearing tumor cells.
Although suggestive, the number of patients in each group is small and not enough for a definitive comparison. Notably, glucocorticoids (including prednisone) which are usually administered with abiraterone to suppress mineralocorticoid excess, may also suppress abiraterone-mediated progesterone up-regulation 11 . Furthermore, as the authors point out, it is possible that selection for the AR T878A mutation is not directly due to progesterone and is instead driven by another 21-carbon steroid that serves as an AR agonist in this context.
The most important clinical implication of these findings by Chen and colleagues is that this study seems to have identified a therapeutically exploitable mechanism of abirateroneresistance. Enzalutamide is effective in blocking the AR T878A mutation 12 . This observation 
